Smithfield Trust’s ResMed RMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$93K Sell
470
-244
-34% -$50.6K ﹤0.01% 511
2026
Q1
$159K Buy
714
+10
+1% +$2.49K 0.01% 405
2025
Q4
$169K Sell
704
-400
-36% -$102K 0.01% 385
2025
Q3
$303K Buy
1,104
+400
+57% +$109K 0.01% 290
2025
Q2
$182K Sell
704
-16
-2% -$3.82K 0.01% 353
2025
Q1
$161K Buy
720
+16
+2% +$3.73K 0.01% 376
2024
Q4
$160K Buy
704
+200
+40% +$48.2K 0.01% 378
2024
Q3
$124K Buy
504
+38
+8% +$8.49K 0.01% 421
2024
Q2
$89K Buy
466
+196
+73% +$39.8K ﹤0.01% 459
2024
Q1
$54K Hold
270
﹤0.01% 553
2023
Q4
$46K Sell
270
-2
-0.7% -$307 ﹤0.01% 566
2023
Q3
$40K Buy
272
+2
+0.7% +$362 ﹤0.01% 566
2023
Q2
$58K Hold
270
﹤0.01% 530
2023
Q1
$59K Hold
270
﹤0.01% 501
2022
Q4
$56K Hold
270
﹤0.01% 501
2022
Q3
$58K Hold
270
﹤0.01% 481
2022
Q2
$57K Hold
270
﹤0.01% 517
2022
Q1
$65K Hold
270
﹤0.01% 519
2021
Q4
$70K Hold
270
﹤0.01% 513
2021
Q3
$71K Hold
270
﹤0.01% 507
2021
Q2
$67K Hold
270
﹤0.01% 508
2021
Q1
$52K Hold
270
﹤0.01% 548
2020
Q4
$57K Hold
270
﹤0.01% 503
2020
Q3
$46K Buy
270
+170
+170% +$31.4K ﹤0.01% 520
2020
Q2
$19K Hold
100
﹤0.01% 632
2020
Q1
$15K Sell
100
-1,378
-93% -$219K ﹤0.01% 625
2019
Q4
$229K Buy
1,478
+216
+17% +$31.1K 0.02% 259
2019
Q3
$171K Buy
1,262
+222
+21% +$29.1K 0.02% 291
2019
Q2
$127K Buy
1,040
+940
+940% +$104K 0.01% 352
2019
Q1
$10K Hold
100
﹤0.01% 678
2018
Q4
$11K Hold
100
﹤0.01% 652
2018
Q3
$12K Hold
100
﹤0.01% 704
2018
Q2
$10K Hold
100
﹤0.01% 740
2018
Q1
$10K Hold
100
﹤0.01% 730
2017
Q4
$8K Buy
+100
New +$8.26K ﹤0.01% 791
2016
Q4
Sell
-83
Closed -$5K 825
2016
Q3
$5K Hold
83
﹤0.01% 761
2016
Q2
$5K Buy
+83
New +$4.89K ﹤0.01% 751
2014
Q1
Sell
-300
Closed -$14K 858
2013
Q4
$14K Buy
+300
New +$15.2K ﹤0.01% 651
2013
Q3
Sell
-5,080
Closed -$230K 765
2013
Q2
$230K Buy
+5,080
New +$241K 0.06% 269

Other funds holding RMD

Smithfield Trust's RMD Position: Q2 2026 in Review

Smithfield Trust reduced its ResMed (RMD) stake by 34% in Q2 2026, selling an estimated $50.6K and leaving 470 shares worth $93K. The position accounts for ﹤0.01% of the portfolio, ranked #511.

Smithfield Trust first reported a position in RMD in Q2 2013 and has held it in 39 quarters since. The position peaked at $303K in Q3 2025. 882 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

  • Smithfield Trust held 470 shares of ResMed worth $93K as of Q2 2026.
  • Smithfield Trust sold 244 ResMed shares in Q2 2026, an estimated $50.6K.
  • ResMed made up ﹤0.01% of Smithfield Trust's portfolio in Q2 2026, its #511 holding.
  • Smithfield Trust first reported a position in ResMed in Q2 2013 and has held it in 39 quarters since.
  • Smithfield Trust's ResMed position peaked at $303K in Q3 2025.
  • 882 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on Smithfield Trust's 13F filing for Q2 2026, filed 5 Aug 2026.